REducing Microvascular Dysfunction in Patients With Angina, Ischaemia and unobstructED coronarY Arteries - a PILOT Study
To demonstrate the feasibility and efficacy of the CS Reducer for the treatment of patients with ischaemia and non-obstructed coronary arteries (INOCA) and coronary microvascular dysfunction (CMD) and through a nested mechanistic substudy investigate the physiological responses in the coronary microcirculation responsible for changes in myocardial perfusion.
• Age \>18 years
• Ongoing symptomatic angina, CCS Class II-IV, for ≥3 months despite background treatment with at least two anti-anginal drug at the maximal tolerated dose.
• Patients willing to consider no change in anti-anginal drug treatment for the duration of their participation in the trial.
• Unobstructed coronary arteries with ≤50% epicardial stenoses demonstrated on coronary angiography.
• Stress-induced hypoperfusion on CMR (Global MPR ≤ 2.2).
• Willingness to comply with the specified follow-up evaluation and to be contactable during the period of the trial.
• Understands the nature of the trial procedures and provides written informed consent.